Leap Therapeutics Inc - LPTX Net earnings per share for the last four quarters

The annual EPS TTM YoY trend for Leap Therapeutics, Inc. (LPTX) demonstrates the resilience of its gastric cancer therapy patents, which create a defensive barrier. However, the high cost of rare tumor trials and FDA safety requirements remain significant risks. The -15.20 metric confirms the current level, while dependence on Asian supplies and logistics determines the overall stability of the business.
LPTX (Leap Therapeutics Inc): analytical breakdowns and indicator data

The development of innovative immunotherapeutic treatments for gastrointestinal cancer places Leap Therapeutics, Inc. (LPTX) in the category of high-risk assets with potential for exponential growth. By analyzing the YoY ttm earnings per share growth chart, an investor assesses the net income dynamics over the year, which allows for a comparison of current business efficiency against market capitalization and determines the company's stage of fundamental development.